Header Logo

Connection

Charles Feldman to Anti-Bacterial Agents

This is a "connection" page, showing publications Charles Feldman has written about Anti-Bacterial Agents.
Connection Strength

7,487
  1. Community-acquired pneumonia: still a major burden of disease. Curr Opin Crit Care. 2016 10; 22(5):477-84.
    View in: PubMed
    Score: 0,455
  2. Adherence to SATS antibiotic recommendations in patients with community acquired pneumonia in Johannesburg, South Africa. J Infect Dev Ctries. 2016 Apr 28; 10(4):347-53.
    View in: PubMed
    Score: 0,442
  3. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012; 2012:584262.
    View in: PubMed
    Score: 0,338
  4. Antibiotic resistance of pathogens causing community-acquired pneumonia. Semin Respir Crit Care Med. 2012 Jun; 33(3):232-43.
    View in: PubMed
    Score: 0,338
  5. Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs. 2011 Jan 22; 71(2):131-53.
    View in: PubMed
    Score: 0,307
  6. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics. Int J Antimicrob Agents. 2010 Jul; 36(1):95-7.
    View in: PubMed
    Score: 0,290
  7. Therapy for pneumococcal bacteremia: monotherapy or combination therapy? Curr Opin Infect Dis. 2009 Apr; 22(2):137-42.
    View in: PubMed
    Score: 0,271
  8. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother. 2007 Nov; 60(5):1155-8.
    View in: PubMed
    Score: 0,243
  9. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother. 2007 Feb; 59(2):224-9.
    View in: PubMed
    Score: 0,232
  10. Controversies in the treatment of pneumococcal community-acquired pneumonia. Future Microbiol. 2006 Oct; 1(3):271-81.
    View in: PubMed
    Score: 0,228
  11. Vaccines in the fight against antimicrobial resistance - perspectives from South Africa. S Afr Med J. 2024 09 02; 114(9):e2111.
    View in: PubMed
    Score: 0,197
  12. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004 Aug; 98(8):708-20.
    View in: PubMed
    Score: 0,196
  13. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med. 2004 May; 143(5):269-83.
    View in: PubMed
    Score: 0,192
  14. The Global Burden of Community-Acquired Pneumonia in Adults, Encompassing Invasive Pneumococcal Disease and the Prevalence of Its Associated Cardiovascular Events, with a Focus on Pneumolysin and Macrolide Antibiotics in Pathogenesis and Therapy. Int J Mol Sci. 2023 Jul 03; 24(13).
    View in: PubMed
    Score: 0,182
  15. A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa. Int J Antimicrob Agents. 2020 Dec; 56(6):106189.
    View in: PubMed
    Score: 0,150
  16. International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. Chest. 2020 11; 158(5):1912-1918.
    View in: PubMed
    Score: 0,149
  17. The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia. Semin Respir Crit Care Med. 2020 Aug; 41(4):455-469.
    View in: PubMed
    Score: 0,147
  18. Pneumococcal virulence factors in community-acquired pneumonia. Curr Opin Pulm Med. 2020 05; 26(3):222-231.
    View in: PubMed
    Score: 0,146
  19. Genomic analysis of a multidrug-resistant clinical Providencia rettgeri (PR002) strain with the novel integron ln1483 and an A/C plasmid replicon. Ann N Y Acad Sci. 2020 02; 1462(1):92-103.
    View in: PubMed
    Score: 0,140
  20. The ketolide antimicrobial agent HMR-3004 inhibits neutrophil superoxide production by a membrane-stabilizing mechanism. Int J Immunopharmacol. 1999 Jun; 21(6):365-77.
    View in: PubMed
    Score: 0,137
  21. The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J. 1999 May; 13(5):1022-8.
    View in: PubMed
    Score: 0,136
  22. Clostridium difficile infection in Johannesburg, South Africa. Hosp Pract (1995). 2018 Dec; 46(5):287-294.
    View in: PubMed
    Score: 0,131
  23. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respir Med. 2018 07; 140:115-121.
    View in: PubMed
    Score: 0,128
  24. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation. 1997 Dec; 21(6):655-65.
    View in: PubMed
    Score: 0,123
  25. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. Infect Dis (Lond). 2018 Jan; 50(1):13-20.
    View in: PubMed
    Score: 0,120
  26. HIV-related pneumococcal disease prevention in adults. Expert Rev Respir Med. 2017 03; 11(3):181-199.
    View in: PubMed
    Score: 0,117
  27. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation. 1996 Dec; 20(6):693-705.
    View in: PubMed
    Score: 0,115
  28. Antimicrobial stewardship across 47 South African hospitals: an implementation study. Lancet Infect Dis. 2016 09; 16(9):1017-1025.
    View in: PubMed
    Score: 0,111
  29. Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus. Semin Respir Crit Care Med. 2016 Apr; 37(2):214-29.
    View in: PubMed
    Score: 0,110
  30. Treating patients who have Klebsiella pneumoniae pneumonia. Chest. 1996 Feb; 109(2):587-8.
    View in: PubMed
    Score: 0,109
  31. Updated recommendations for the management of upper respiratory tract infections in South Africa. S Afr Med J. 2015 Apr 06; 105(5):344-52.
    View in: PubMed
    Score: 0,103
  32. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med. 1995 Mar; 89(3):187-92.
    View in: PubMed
    Score: 0,102
  33. Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010. Antimicrob Agents Chemother. 2014 Jun; 58(6):3293-305.
    View in: PubMed
    Score: 0,096
  34. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol. 2013 Jan; 51(1):369-72.
    View in: PubMed
    Score: 0,087
  35. The spread of carbapenem-resistant Enterobacteriaceae in South Africa: risk factors for acquisition and prevention. S Afr Med J. 2012 May 10; 102(7):599-601.
    View in: PubMed
    Score: 0,084
  36. Guideline summary: appropriate use of tigecycline. S Afr J Surg. 2012 Feb 14; 50(1):20-1.
    View in: PubMed
    Score: 0,083
  37. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt). 2012 Feb; 13(1):43-9.
    View in: PubMed
    Score: 0,082
  38. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med. 2011 Sep; 32(3):535-46.
    View in: PubMed
    Score: 0,080
  39. Guideline: appropriate use of tigecycline. S Afr Med J. 2010 Jun 01; 100(6 Pt 2):388-94.
    View in: PubMed
    Score: 0,073
  40. New insights into pneumococcal disease. Respirology. 2009 Mar; 14(2):167-79.
    View in: PubMed
    Score: 0,067
  41. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect. 2007 Feb; 13(2):162-171.
    View in: PubMed
    Score: 0,058
  42. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. Int J Tuberc Lung Dis. 2006 Jul; 10(7):739-43.
    View in: PubMed
    Score: 0,056
  43. Appropriate use of the carbapenems. S Afr Med J. 2004 Oct; 94(10 Pt 2):857-61.
    View in: PubMed
    Score: 0,050
  44. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004 Aug 15; 170(4):440-4.
    View in: PubMed
    Score: 0,048
  45. Guideline for the management of upper respiratory tract infections. S Afr Med J. 2004 Jun; 94(6 Pt 2):475-83.
    View in: PubMed
    Score: 0,048
  46. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect. 2002; 8 Suppl 2:12-42.
    View in: PubMed
    Score: 0,041
  47. Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. Respirology. 2001 Dec; 6(4):323-30.
    View in: PubMed
    Score: 0,041
  48. Streptococcus pneumoniae respiratory tract infections. Curr Opin Infect Dis. 2001 Apr; 14(2):173-9.
    View in: PubMed
    Score: 0,039
  49. Investigation of the anti-inflammatory and membrane-stabilizing potential of spiramycin in vitro. J Antimicrob Chemother. 2000 Aug; 46(2):269-71.
    View in: PubMed
    Score: 0,037
  50. Genomic analysis of two drug-resistant clinical Morganella morganii strains isolated from UTI patients in Pretoria, South Africa. Lett Appl Microbiol. 2020 Jan; 70(1):21-28.
    View in: PubMed
    Score: 0,035
  51. Effect of dirithromycin on Haemophilus influenzae infection of the respiratory mucosa. Antimicrob Agents Chemother. 1998 Apr; 42(4):772-8.
    View in: PubMed
    Score: 0,032
  52. From guidelines to practice: a pharmacist-driven prospective audit and feedback improvement model for peri-operative antibiotic prophylaxis in 34 South African hospitals. J Antimicrob Chemother. 2017 04 01; 72(4):1227-1234.
    View in: PubMed
    Score: 0,029
  53. The role of appropriate diagnostic testing in acute respiratory tract infections: An antibiotic stewardship strategy to minimise diagnostic uncertainty in primary care. S Afr Med J. 2016 May 10; 106(6):30-7.
    View in: PubMed
    Score: 0,028
  54. Community-acquired pneumonia in the ICU. Chest. 1995 Apr; 107(4):1182-3.
    View in: PubMed
    Score: 0,026
  55. Increased risk of death in human immunodeficiency virus-infected children with pneumococcal meningitis in South Africa, 2003-2005. Pediatr Infect Dis J. 2011 Dec; 30(12):1075-80.
    View in: PubMed
    Score: 0,020
  56. Comparison of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit. Respiration. 1991; 58(5-6):265-70.
    View in: PubMed
    Score: 0,019
  57. Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect. 1990 Jan; 20(1):21-31.
    View in: PubMed
    Score: 0,018
  58. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis. 2005 Aug 15; 41(4):554-6.
    View in: PubMed
    Score: 0,013
  59. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003 Jul 15; 37(2):230-7.
    View in: PubMed
    Score: 0,011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.